Drugs / Maplirpacept
Trials 9 · a red edge is where a trial was stopped
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-06-13 | Incyte Corporation | Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47 incyte.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Maplirpacept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03530683 ↗ |
| Known as | PF-07901801 | “The purpose of this clinical trial is to learn how the experimental medicine maplirpacept (PF-07901801) affects people with various types of blood cancers:” NCT03530683 ↗3“maplirpacept (PF-07901801) administered in combination with PLD” NCT05261490 ↗ “maplirpacept (PF-07901801)” NCT05567887 ↗ “maplirpacept (PF-07901801)” NCT05896163 ↗ |
| Known as | SIRP.ALPHA.-IGG4 F | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802185 ↗ |
| Known as | TTI-622 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05139225 ↗ |
| Action | Inhibit | “Neutralization of the inhibitory CD47 signal” NCT05567887 ↗ |
| Modality | Protein / enzyme biologic | “CD47 Blockade With SIRP-Alpha FC Fusion Proteins (TTI-622)” NCT05139225 ↗ |
| Route | Intravenous | “maplirpacept (PF-07901801) will be administered by intravenous infusion” NCT03530683 ↗ |
| Target | CD47 | “preventing CD47 from delivering its antiphagocytic signal” NCT05567887 ↗ |